Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ITI Life Sciences: Scotland Minds the Funding Gap

This article was originally published in Start Up

Executive Summary

Scotlands ITI Life Sciences aims to create a unique model for plugging the widening funding gap between publicly funded research and venture-funded commercialization of technology. The firm's first four programs reflect the various ways it aims to drum up life sciences business in Scotland.

You may also be interested in...



Inverness Buys Bulk

Inverness Medical Innovations, a point-of-care diagnostics company, made a splash with its $1.6 billion acquisition of Biosite. But the purchase was merely the latest step in a long-time strategy of growing through acquisition.

Inverness Buys Bulk

Inverness Medical Innovations, a point-of-care diagnostics company, made a splash with its $1.6 billion acquisition of Biosite. But the purchase was merely the latest step in a long-time strategy of growing through acquisition.

German Biotech: Coalescing around the Haves

Positive signs are coming out of German biotech for the first time in years. Scientific output remains strong. The subsector boasts its first profitable pharmaceutical-oriented company; several on- or near-market products, and even a nascent IPO market. The fact that dozens of companies are expected to go bust this year is another sign of the industry's maturation. The long-awaited consolidation predicted in the wake of the Neuer Markt demise is seemingly finally happening. The have-nots are finally beginning to cluster around the haves.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

SC091084

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel